Being able to target Breast Cancer cells, with peptides specifically designed to identify and destroy breast cancer cells is beginning to gain a foothold as a highly efficient approach to selectively deliver targeted destruction to cancer cells with minimal cellular toxicity.
Even the highly aggressive form of breast cancer HER2+ is being down regulated by the utilization of peptide enhanced therapies.. The new polymalic acid-based mini nanodrugsare peptides are synthesized and specifically characterized to inhibit growth of HER2+ breast cancer. These mini nanodrugs are highly effective and may soon be able to be substituted for Trastuzumab. The addition of the peptides have caused the HER2+ cells to be recognized, targeted and destroyed by the polymer-attached trastuzumab-mimetic 12-mer peptide at a faster and safer rate than ever, preventing cancer cell proliferation and and causing a significant reduction in tumor size by more than 15 times vs. untreated control group.